Abstract
Cancer immunotherapy has shown remarkable progress in recent years. Nanocarriers, such as liposomes, have favorable advantages with the potential to further improve cancer immunotherapy and even stronger immune responses by improving cell type-specific delivery and enhancing drug efficacy. Liposomes can offer solutions to common problems faced by several cancer immunotherapies, including the following: (1) Vaccination: Liposomes can improve the delivery of antigens and other stimulatory molecules to antigen-presenting cells or T cells; (2) Tumor normalization: Liposomes can deliver drugs selectively to the tumor microenvironment to overcome the immune-suppressive state; (3) Rewiring of tumor signaling: Liposomes can be used for the delivery of specific drugs to specific cell types to correct or modulate pathways to facilitate better anti-tumor immune responses; (4) Combinational therapy: Liposomes are ideal vehicles for the simultaneous delivery of drugs to be combined with other therapies, including chemotherapy, radiotherapy, and phototherapy. In this review, different liposomal systems specifically developed for immunomodulation in cancer are summarized and discussed.
Highlights
Cancer immunotherapy has shown remarkable progress in recent years
The cancer antigens can be presented into the major histocompatibility complex (MHC) class II molecules or cross-presented into the MHC class I molecules on dendritic cells (DCs) that migrate to draining lymph nodes to initiate T cell activation [3]
We have summarized the therapeutic strategies of immunomodulation in recent years and discuss the different mechanisms used to intervene with tumor immunity through the application of liposome technology
Summary
Cancer immunotherapy has been widely explored because of its durable and robust effects [1]. Tumors are more than just insular masses consisting of proliferating cancer cells; they have a complex composition built by multiple cell types, which participate in heterotypic interactions with each other [2]. Sustained antitumor responses triggered by immunotherapeutic treatments have been demonstrated via the active stimulation of specific targets such as immune cells, normalization of the tumor microenvironment (TME), and other mechanisms
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
